Staging preview: health content pending qualified review
D2C Peptides
KLOW Peptide Blend vial

KLOW Peptide Blend 70 mg

Also searched as: klow, klow peptide, klow blend

Sold as KLOW Peptide Blend - 70mg

$95 In stock

Strength
Ships from

For research use only. Not for human or veterinary use.

Ships from the USA or Canada. Shipping details

KLOW Peptide Blend is a research mix of four peptides, BPC-157, TB-500, KPV and GHK-Cu, freeze-dried together in one vial that holds 70 mg of powder in total. The amount of each peptide is not disclosed. No published study has tested this combination in animals or people,1 and KLOW is not an FDA-approved drug.2

Specifications

ComponentsBPC-157, TB-500, KPV and GHK-Cu, combined in one freeze-dried powder
Vial contents70 mg of freeze-dried (lyophilized) powder in total; the amount of each peptide is not disclosed
BPC-15715 amino acids, GEPPPGKPADDAGLV; C62H98N16O22; 1419.5 g/mol; CAS 137525-51-0; PubChem CID 9941957567
TB-500Ac-LKKTETQ, the acetylated 7-amino-acid fragment of thymosin beta-4 that FDA defines as TB-500; C38H68N10O14; 889.0 g/mol; CAS 885340-08-9; PubChem CID 627076623589
KPV3 amino acids, Lys-Pro-Val; C16H30N4O4; 342.43 g/mol; CAS 67727-97-3; PubChem CID 1256725610
GHK-CuGly-His-Lys bound to copper; the form in the vial is not stated. Values for prezatide copper (1:1 complex): C14H23CuN6O4+; 402.92 g/mol; CAS 89030-95-5; PubChem CID 71587328111213
Strength70 mg
Ships fromUSA, Canada
CategoriesAnti-Aging Peptides, Growth Hormone Peptides, Healing and Recovery Peptides, Muscle Growth Peptides, Sleep and Stress Peptides, Weight Loss Peptides
StorageNo stability study of the four peptides mixed together has been published.1 For the single powders, figures cited by FDA point to dry, frozen storage: BPC-157 below -18 °C, TB-500 up to 1 year at -20 °C and KPV free base up to 3 years at -20 °C.234

Supplies for KLOW Peptide Blend

Bulk and wholesale orders

Labs that need KLOW in larger quantities, or a steady KLOW peptide supplier, can apply for a wholesale account. Bulk terms are confirmed on application.

Wholesale detailsApply for a wholesale account

Questions about KLOW Peptide Blend

About KLOW Peptide Blend

KLOW combines four peptides that each have their own research record. BPC-157 is a 15-amino-acid fragment of body protection compound (BPC), a protein first isolated from human gastric juice.25 TB-500 copies amino acids 17 to 23 of thymosin beta-4, a 43-amino-acid peptide, with an acetyl group added.3 KPV is a three-amino-acid fragment of alpha-MSH, a hormone made in the pituitary gland.4 GHK is a tripeptide found in human plasma, saliva and urine, and it is thought to act as a complex with copper.11

This page lists KLOW peptide for sale as one 70 mg vial, with the KLOW peptide price and stock for each shipping origin shown in the selector above. The four peptides come premixed in amounts that are not disclosed, so studies that need a known amount of one peptide can use the separate BPC-157, TB-500, KPV and GHK-Cu vials.

Read What is KLOW Peptide Blend? for the evidence on each component, and its limits, before you buy KLOW peptide online for a study.

Research highlights

  • No study of the blend (database search, October 2026). A PubMed search for BPC-157 together with KPV and GHK returned 0 records.1
  • Two of the parts together, in rats (2026). In 32 rats after Achilles tendon repair, 4 weeks of BPC-157 plus TB-500 worked no better than either alone; of the single-peptide groups, only TB-500 raised load to failure significantly over controls.14
  • BPC-157 in people (2026 systematic review). Three small uncontrolled studies, 30 people in total; certainty of evidence rated very low.15
  • TB-500 and KPV in people. FDA's 2026 reviews found no clinical studies and no human exposure data for either peptide by any route.34
  • KPV in mice (2008). Given by mouth in drinking water, KPV reduced chemically induced colitis in two mouse models.16
  • GHK-Cu gel in people (1994). In a randomized, placebo-controlled trial in diabetic neuropathic ulcers, a GHK-copper gel gave a median 98.5% closure of plantar ulcer area, against 60.8% with plain gel.17
  • Safety signals in animals (BPC-157). FDA reports altered clotting times and liver-related blood changes, such as raised ALT, in rats and dogs given BPC-157 into muscle daily for 28 days.2

Regulatory status

FDA states that BPC-157, TB-500 and KPV are not components of any FDA-approved drug.234 Ahead of a July 2026 advisory committee meeting, FDA staff proposed not adding them to the 503A bulks list, the bulk substances pharmacies may use to compound.234 Trade press reported an 8 to 6 committee vote, with one abstention, in favor of allowing them to be compounded; FDA is not bound by it, and any change would require formal rulemaking.18 As of October 24, 2026, a Federal Register search for BPC-157 found no proposed rule.19 FDA also says compounded injectable GHK-Cu may pose a risk of immune reactions, with limited human data.20 In sport, BPC-157 is prohibited under WADA class S0 and TB-500 under S2.2122 Every vial is labeled: For research use only. Not for human or veterinary use.

Handling and storage

The single peptides dissolve to different limits. Figures cited by FDA put the water solubility of BPC-157 at 5 mg/mL2 and TB-500 at 50 mg/mL.3 KPV free base dissolves only up to 0.70 mg/mL, against 5 mg/mL for KPV acetate,4 and the listing does not say which form the vial holds. FDA adds that peptides such as BPC-157 can be sensitive to pH, heat, concentration and impurities, which may make them clump and break down.2 The lab steps are in the reconstitution guide, and the reconstitution calculator works out the concentration for a chosen diluent volume.

Frequently asked questions

Where can I buy KLOW peptide?

D2C Peptides sells KLOW Peptide Blend as one 70 mg research vial; the selector on this page shows price and stock. Orders ship from the USA and Canada to addresses across the United States; delivery details are on the shipping page. KLOW is sold for laboratory research only, under the research use policy.

How much does a vial of KLOW peptide cost?

One 70 mg vial is listed at $95. That covers the freeze-dried powder only; bacteriostatic water, syringes and swabs are listed separately as supplies. Because the amount of each peptide is not disclosed, cost per milligram works out for the whole blend only, not for any single peptide.

How should KLOW be stored when it arrives?

Keep the vial sealed, dry and frozen until it is mixed. Manufacturer data cited by FDA say freeze-dried BPC-157 is stable for 3 weeks at room temperature but should be stored desiccated below -18 °C, as moisture greatly reduces the long-term stability of freeze-dried peptides.25 The TB-500 data sheet FDA cites also calls for protection from light.3 Handling after mixing is in the peptide storage guide.

Is there a certificate of analysis for KLOW?

Check the lab results page for a certificate of analysis for your lot. For a blend, look for a certificate that confirms the identity and amount of each of the four peptides, not only overall purity. FDA found that most certificates it located for BPC-157 and for KPV showed only a purity result, with no impurity limits or impurity test results.24

What supplies are used with a KLOW vial?

The powder is mixed with a diluent such as bacteriostatic water, measured with syringes and handled with alcohol swabs. The reconstitution calculator gives the total concentration from vial size and diluent volume. These are lab handling steps, not directions for use in people.

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. PubMed search: (BPC-157 OR "BPC 157") AND KPV AND GHK. National Library of Medicine (PubMed E-utilities), 2026.
  2. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), PCAC Meeting July 23-24, 2026. U.S. Food and Drug Administration, 2026.
  3. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). U.S. Food and Drug Administration, 2026.
  4. FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA briefing document for the July 23-24, 2026 PCAC meeting (memo dated 5/12/2026). U.S. Food and Drug Administration, 2026.
  5. FDA presentations, Pharmacy Compounding Advisory Committee, July 23, 2026: peptide sequences of BPC-157, KPV and TB-500. U.S. Food and Drug Administration, 2026.
  6. PubChem compound properties: BPC-157 (CID 9941957) and KPV (CID 125672). PubChem, National Center for Biotechnology Information, 2026.
  7. PubChem CAS record: BPC-157 (CID 9941957). PubChem, National Center for Biotechnology Information, 2026.
  8. PubChem Compound CID 62707662 (TB-500): computed properties. PubChem, National Center for Biotechnology Information (NIH), 2026.
  9. PubChem CAS record: TB-500, UNII-QHK6Z47GTG (CID 62707662). PubChem, National Center for Biotechnology Information, 2026.
  10. PubChem CAS record: KPV, Msh (11-13) (CID 125672). PubChem, National Center for Biotechnology Information, 2026.
  11. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (Pickart L et al.): origin and copper. BioMed Research International, 2015.
  12. PubChem CID 71587328, Prezatide copper (properties). PubChem, NIH National Library of Medicine, 2026.
  13. PubChem CAS record: prezatide copper (CID 71587328). PubChem, National Center for Biotechnology Information, 2026.
  14. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer O et al.). Joint Diseases and Related Surgery, 2026.
  15. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety (Poolton JT, Minett J, Kazmi A; PMID 42885452). Acta Orthopaedica Belgica (PubMed abstract via NCBI E-utilities), 2026.
  16. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso G et al.). Gastroenterology, 2008.
  17. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (Mulder GD et al.). Wound Repair and Regeneration, 1994.
  18. FDA Panel Votes to Loosen Restrictions for Four Peptides. Pharmaceutical Executive (PharmExec), 2026.
  19. Federal Register API search: documents matching 'BPC-157'. Office of the Federal Register, National Archives, 2026.
  20. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (GHK-Cu, injectable routes). U.S. Food and Drug Administration, 2026.
  21. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide (status). U.S. Anti-Doping Agency (USADA).
  22. Athlete Advisory: What’s New on the 2027 WADA Prohibited List? (named peptides). U.S. Anti-Doping Agency (USADA), 2026.
Shop all peptidesMore anti-aging peptides